Buy or Sell Medtronic Stock Now?
Medtronic (NYSE:MDT) will report earnings on Tuesday, August 19, 2025. Over the last five years, the stock's next-day move following results has been highly unpredictable: it posted a positive one-day...
Fiscal Year: May - April
Medtronic plc (MDT), listed on the NYSE, has a market capitalization of $. As of Aug 19, 2025, the stock is trading at $92.81 per share, offering investors a clear view of its current market value. Medtronic plc is a prominent player in the industry sector, attracting both institutional and retail investors due to its performance and potential.
With a P/E ratio of 25.71, investors can assess the stock's valuation in comparison to its earnings. A P/E ratio is a crucial indicator for value investors, showing whether the stock is over or undervalued relative to its current earnings. Medtronic plc also offers a dividend yield of 3.06%, making it an attractive option for income-focused investors who seek regular dividends.
Our Discounted Cash Flow (DCF) analysis reveals that Medtronic plc (MDT) may be overvalued compared to its intrinsic worth. However, to see the exact DCF fair value, please Login or Upgrade for access.
The proprietary SS Score for Medtronic plc is a unique metric that analyzes the company's financial health and growth potential. The score takes into account critical factors such as revenue growth, net income, free cash flow (FCF) compound annual growth rate (CAGR), the trend of shares outstanding, and the debt-to-FCF ratio. This helps investors to make a more informed decision, as an undervalued stock might still have poor financial fundamentals.
To view the detailed SS Score for Medtronic plc, Login or Upgrade for access.
The Price to Free Cash Flow (P/FCF) ratio for Medtronic plc is 22.93, offering insights into how much investors are paying for the company's free cash flow. A lower P/FCF ratio typically suggests that the stock is undervalued, while a higher ratio may indicate overvaluation.
In summary, Medtronic plc (MDT) has shown consistent financial performance, as illustrated by the financial charts above, which track its revenue growth, net income, free cash flow, and shares outstanding over the past several years. These metrics provide investors with key insights into the company's past and projected future performance. Investors should use the SS Score alongside the DCF Fair Value to make better-informed decisions about whether to buy or hold the stock.
*This analysis is for informational purposes only and does not constitute investment advice. Always read the company's 10-K filings and do your own research before making any investment decisions.
Whether Medtronic plc (MDT) is a good stock to buy depends on various factors, including its financial health, market conditions, and your investment strategy. Our analysis indicates that the stock may be overvalued compared to its intrinsic value. However, it is important to assess the SS Score and review the company's fundamentals before making any investment decisions.
The fair value of Medtronic plc (MDT) is determined through our Discounted Cash Flow (DCF) analysis. This value represents the intrinsic worth of the stock based on its expected future cash flows. To view the specific fair value, consider subscribing to our service for complete access.
The SS Score is a proprietary financial quality metric that assesses factors such as revenue growth, net income, free cash flow growth, and debt levels. It helps investors evaluate the overall financial health of Medtronic plc. To access the full SS Score, consider upgrading your subscription.
Medtronic plc is a significant player in the industry sector, with a market capitalization of $ and a competitive P/E ratio of 25.71. Investors should compare these metrics with industry peers to gauge whether Medtronic plc is outperforming or underperforming within its sector.
Medtronic (NYSE:MDT) will report earnings on Tuesday, August 19, 2025. Over the last five years, the stock's next-day move following results has been highly unpredictable: it posted a positive one-day...
Medtronic plc MDT will release financial results for the first quarter before the opening bell on Tuesday, Aug. 19.
GALWAY, Ireland , Aug. 14, 2025 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE:MDT) on Thursday, August 14, 2025, approved the company's cash dividend for the second quarter of fiscal y...
CHICAGO--(BUSINESS WIRE)--FourKites®, the global leader in AI-driven supply chain transformation, today announced that Dov Shenkman, CEO and Founding Member of Atid Group LLC, has joined its Strategic...
GALWAY, Ireland , Aug. 5, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that it will report financial results on Tuesday, August 19, 2025, f...
Medtronic (NYSE:MDT), which is renowned for inventing the world's first battery-operated implantable pacemaker, has over time earned respect as a worldwide leader in medical technology and has created...
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
• Ligand to invest $35 million in exchange for a tiered royalty on future sales of Orchestra's AVIM therapy and Virtue SAB and an additional $5 million in an equity private placement • Medtronic to i...
Medtronic's decade-long underperformance stems from stagnant revenue growth, declining margins, and inconsistent returns on invested capital, despite a solid dividend history. The Diabetes segment spi...
GALWAY, Ireland , July 21, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in medical technology, today announced CE (Conformité Européenne) Mark in Europe to expand indications of the...
GALWAY, Ireland , July 8, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced the appointment of Chad Spooner as chief financial officer (CFO) of ...
Initiate Medtronic with Strong Buy, $161 PT, citing a structural margin inflection from Diabetes spin-off and robust innovation pipeline (120+ approvals). Street underestimates FY27 margin/EPS upside ...
I reiterate my buy rating on Medtronic, driven by solid fundamentals and an attractive valuation, despite less upside versus prior estimates. Medtronic continues to deliver steady revenue growth, robu...
GALWAY, Ireland , June 23, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that its Board of Directors appointed Dr. Joon Lee, CEO at Emory He...
Now is an opportune time to focus on income stocks like that offer value and stability amid market volatility. I focus on 2 Dividend Aristocrats that are attractively valued while supporting well-cove...
Medtronic remains a dependable dividend aristocrat, but its long-term total shareholder returns lag significantly behind peers like Johnson & Johnson and Stryker. Despite a solid 2025 performance, the...
Medtronic plc MDT announced on May 21 its plans to separate its Diabetes business into a separate, publicly traded company. The separation will occur via a two step transaction – an initial minority I...
GALWAY, Ireland , June 12, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced MiniMed as the name for the planned New Diabetes Company following ...
Deal OverviewOn May 21, 2025, Medtronic plc (NYSE: MDT; $87.44, Market Capitalization: $112.1 billion), a global leader in medical technology, announced its intent to spin off its Diabetes business in...
Dividend growth remains robust for select companies, with Casey's, Oil-Dri, and Matson poised for double-digit increases based on strong earnings and expansion. Caterpillar and Kroger are expected to ...
The market continues to chase growth while ignoring once beloved income stocks. Verizon offers a compelling 6.3% dividend yield, robust free cash flow, and trades well below its historical valuation, ...
Medtronic plc (NYSE:MDT) Bernstein's 41st Strategic Decisions Conference Call May 29, 2025 11:00 AM ET Company Participants Geoff Martha - Chairman and Chief Executive Officer Thierry Pieton - Execut...
I love luxury watches, but buying more to "earn" access to rarer models made me realize how easy it is to waste capital chasing ego-driven goals. Unlike watches, dividend growth stocks offer reliable ...
Upgrading Medtronic to 'Strong Buy' with a $104 fair value, driven by the diabetes business spin-off catalyst. Divesting diabetes enables Medtronic to focus on core cardiac and surgical markets, impro...
Below estimates were sourced from SimplyWallSt and are intended for educational purposes only as a baseline for the analysis.
Year | FCF Estimate | % | # Analysts |
---|---|---|---|
2026 | 5.82B | Analyst x3 | |
2027 | 6.51B | 11.97% | Analyst x3 |
2028 | 6.89B | 5.77% | Analyst x2 |
2029 | 7.14B | 3.62% | Est @3.6% |
2030 | 7.36B | 3.07% | Est @3.1% |
2031 | 7.56B | 2.84% | Est @2.8% |
2032 | 7.77B | 2.69% | Est @2.7% |
2033 | 7.97B | 2.57% | Est @2.6% |
2034 | 8.15B | 2.32% | Est @2.3% |
2035 | 8.34B | 2.28% | Est @2.3% |
Below are the FCF estimates with the discount factor and the calculated present value with the terminal value that led the results above.
Year | FCF | Discount Factor | PV of Future FCF |
---|---|---|---|
2024A | 5.20B | 1.00 | 5.20B |
2025A | 5.19B | 1.00 | 5.19B |
2026E | 5.82B | 1.08 | 5.40B |
2027E | 6.51B | 1.16 | 5.61B |
2028E | 6.89B | 1.25 | 5.50B |
2029E | 7.14B | 1.35 | 5.29B |
2030E | 7.36B | 1.45 | 5.06B |
2031E | 7.56B | 1.57 | 4.83B |
2032E | 7.77B | 1.69 | 4.60B |
2033E | 7.97B | 1.82 | 4.38B |
2034E | 8.15B | 1.96 | 4.16B |
2035E | 8.34B | 2.11 | 3.95B |
Terminal | 162.15B | 2.11 | 76.72B |
The information given by Studying Stocks and provided in the web and/or mobile applications (Platforms) is only factual information and should not be considered financial advice.
Any information contained in this website has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
When creating an account, you acknowledge that you are:
We retain the right to cancel your account for any reason, or refuse your account creation request.
The information on our Platforms is not comprehensive and is intended to provide a summary of the subject matter covered. While we use all reasonable attempts to ensure the accuracy and completeness of the data and information on our Platforms, to the extent permitted by law, we make no warranty regarding the information on these Platforms. You should monitor any changes to the information contained on these Platforms.
Furthermore we make no commitments in regards to the minimum amount of uptime that our platforms will maintain, although we will make ever reasonable attempt to ensure that the platforms are operational. Therefore, any reference of "latest", "current" and related words about the financial data presented here may not be up to date with the financial markets or represent reality of the information.
We are not liable to you or anyone else if interference with or damage to your computer systems occurs in connection with the use of these Platforms or a linked website. You must take your own precautions to ensure that whatever you select for your use from our Platforms is free of viruses or anything else (such as worms or Trojan horses) that may interfere with or damage the operations of your computer systems.
We may, from time to time and without notice, change or add to the Platforms (including the Terms) or the information, products or services described in it. However, we do not undertake to keep the Platforms updated. We are not liable to you or anyone else if errors occur in the information or the Platforms is not up-to-date.
Our Platforms may contain links to websites operated by third parties. Those links are provided for convenience and may not remain current or be maintained. Unless expressly stated otherwise, we do not endorse and are not responsible for the content on those linked websites and have no control over or rights in those linked websites.
These Platforms are for your personal, non-commercial use only. You may not modify, copy, distribute, transmit, display, perform, reproduce, publish, license, commercially exploit, create derivative works from, transfer, or sell any Content, software, products or services contained within these Platforms. You may not use these Platforms, or any of its Content, to further any commercial purpose, including any advertising or advertising revenue generation activity on your own website.
You must not do any act that we would deem to be inappropriate, is unlawful or is prohibited by any laws applicable to these Platforms, including but not limited to:
If we allow you to post any information to our Platforms, we have the right to take down this information at our sole discretion and without notice.
To the maximum extent permitted by law, we make no warranties or representations about these Platforms or the Content, including but not limited to warranties or representations that they will be complete, accurate or up-to-date, that access will be uninterrupted or error-free or free from viruses, or that these Platforms will be secure.
We reserve the right to restrict, suspend or terminate without notice your access to these Platforms, any Content, or any feature of these Platforms at any time without notice and we will not be responsible for any loss, cost, damage or liability that may arise as a result.
To the maximum extent permitted by law, in no event shall we be liable for any direct and indirect loss, damage or expense – irrespective of the manner in which it occurs – which may be suffered due to your use of our Platforms and/or the information or materials contained on it, or as a result of the inaccessibility of these Platforms and/or the fact that certain information or materials contained on it are incorrect, incomplete or not up-to-date.
This website utilises cookies. If you do not have cookies enabled in your web browser some functions of the site may not work as intended.